One dose of Pfizer-BioNTech vaccine offers two-thirds protection from COVID-19
One dose of the Pfizer-BioNTech vaccine offers two-thirds protection against coronavirus, data seen by the U.K. government suggests.
Early findings from the U.K.’s vaccination program, due to be released within days, show that the first dose reduced the symptomatic infection risk among patients by 65% in younger adults and 64% in over-80s, a person familiar with the matter said.
The data, first reported by The Sun newspaper, showed that two doses of the Pfizer vaccine saw protection rise to between 79% and 84%, depending on age. The AstraZeneca vaccine offers similar protection, the newspaper said.Subscribe to The Capsule, a weekly brief monitoring advances in health care and biopharma, delivered free to your inbox.
While efficacy results are lower than those found in Pfizer’s clinical trials, Boris Johnson’s government is likely to hail the U.K.’s first real-world data as a significant boost to its efforts to immunize the population. A successful mass vaccine rollout is key to the government’s hopes of reopening the economy after months of lockdown.
More than 12.6 million people in the U.K. have so far received their first doses of either the Pfizer shot or the Oxford-AstraZeneca vaccine, according to latest data published Tuesday. That includes more than 90% of the over-80s.
Johnson has set a target to immunize almost 15 million people by Feb. 15, focusing on the most vulnerable groups and their carers. After that, his team will consider when and how to begin lifting the U.K.’s third national lockdown, which has been in place for the past month and has compounded the economic damage already done by the country’s deepest recession in more than 300 years.
From March 8, schools could begin to reopen, followed by the easing of other curbs. But while the U.K.’s vaccine rollout is one of the most advanced in the world, the one big doubt is whether the shots will remain effective against new strains of coronavirus.
This week Johnson led efforts to reassure the public that vaccines will still work to prevent the most severe illness and death from the South Africa variant. Some scientists are concerned that the strain is far more widespread in the U.K. and could derail the plan to lift restrictions.
Data from the real world rollout of the U.K.’s two vaccines will be critical in determining how fast the government can begin to ease the lockdown.
Paul Hunter, professor of medicine at the University of East Anglia, said the early results were “quite amazing” and he believed gradual lifting of the curbs would be possible, starting with schools from early March.
“If these numbers are borne out, then they are very reassuring,” Hunter told The Sun. “If they are achieving 65% protection after three weeks with both jabs, then I think that’s really good.”
The government has deployed more surge testing of the population in parts of Lambeth, south London, in an attempt to trace and contain the new strain found there.